Insider Trading Arrangements |
3 Months Ended |
|---|---|
|
Sep. 30, 2026
shares
| |
| Trading Arrangements, by Individual | |
| Non-Rule 10b5-1 Arrangement Adopted | false |
| Rule 10b5-1 Arrangement Terminated | false |
| Non-Rule 10b5-1 Arrangement Terminated | false |
| Richard Young [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | On September 11, 2026, Richard Young, PhD, a member of our board of directors, adopted a trading plan intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information. Pursuant to this plan, Dr. Young may sell up to 50,000 shares of our common stock beginning on December 16, 2026, subject to the terms of the plan. The plan will terminate on or prior to December 15, 2027.
|
| Name | Richard Young |
| Title | member of our board of directors |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | September 11, 2026 |
| Expiration Date | December 15, 2027 |
| Arrangement Duration | 364 days |
| Aggregate Available | 50,000 |
| Daniel Tardiff [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | On September 25, 2026, Daniel Tardiff, PhD, our Chief Scientific Officer, adopted a trading plan intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information. Pursuant to this plan, Dr. Tardiff may sell up to 51,020 shares of our common stock beginning on December 28, 2026, subject to the terms of the plan. The plan will terminate on or prior to September 24, 2027.
|
| Name | Daniel Tardiff |
| Title | Chief Scientific Officer |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | September 25, 2026 |
| Expiration Date | September 24, 2027 |
| Arrangement Duration | 270 days |
| Aggregate Available | 51,020 |